

ISPOR 2014-2015 – A Strong and Successful Society

Nancy S. Berg, ISPOR CEO & Executive Director



The ISPOR 2014-2015 Board of Directors completed their term with a strong and successful Society.

HIGHLIGHTS FROM THIS YEAR INCLUDE:

- A thriving membership with 9500 members and an additional 8000 regional members participating in ISPOR chapters in 114 countries.
- An anniversary celebrating a 20-year history that is shaping the future of health economics and outcomes research.
- Positive results from ISPOR's first membership survey indicating that members place a high value on benefits they receive from the Society.
- Record attendance at European, Asia-Pacific and International meetings.
- Publications with impact.
 - *Value in Health* has a current 5-Year Impact Factor of 3.373 – a 13% increase from 2013.
 - *Value in Health Regional Issues* has applied to be indexed in Medline.
 - *Value and Outcomes Spotlight* – replaces *ISPOR CONNECTIONS* as another resource of scientific information as well as member and industry news.
- Quality educational programs such as short courses and the new ISPOR branded HTA training.
- New *Good Practices for Outcomes Research Reports*, two on modelling health care delivery, one updating an earlier report on Cost-Effectiveness Analysis Alongside Clinical Trials to reflect the advances in analytical approaches and data availability.
- A growing network including 11 new Student Chapters and 10 new Regional Chapters.
- Planning for the future with a strategic review of ISPOR's strategic roadmap, "Vision 2020."
- Healthy finances, ending 2014 with a net surplus and solid portfolio of assets.
- A smooth transition to a new CEO/Executive Director.

(Board member terms are July 1 to June 30.)

Details of Board Actions

The ISPOR Board of Directors is responsible for the overall performance and strategic direction of the Society.

From July 1, 2014 to June 30, 2015 the Board met 5 times (2 in-person and 4 virtual meetings). In addition, the ISPOR Board with other Society leaders and senior staff met in a special strategic planning meeting to begin the process of updating Vision 2020.

Details on the Board of Directors actions follow with these approvals:

Leadership and Strategic Actions:

- In 2014-15, the ISPOR Board made progress in enhancing its discussions and deliberations beyond routine approvals to more dialog focused on the needs of Members, and ISPOR's future.
- Nancy S. Berg was hired as ISPOR's CEO and Executive Director, and joined the Society on October 22, 2014.
- The Nominations Committee reported election of New Officers and Directors:
 - President-Elect 2015-2016: Lou P. Garrison, PhD, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA.
 - 2015-2017 Directors: Nancy Devlin, PhD, Director of Research, Office of Health Economics, London, UK, Manuel Espinoza, MD, MSc, PhD, Professor of Public Health at Pontifical Catholic University of Chile, Santiago, Chile, and Dana Goldman, PhD, Professor and the Leonard D. Schaeffer Director's Chair at the University of Southern California, Los Angeles, CA, USA.

Financial Actions:

- The 2014 ISPOR financial budget and the 2015 business plan and budget were also approved. This action was based off the first Society business plan.
- The Board also received and approved the annual Society audit, conducted by an independent audit firm. The ISPOR audit was approved, having met all requirements for a satisfactory audit.
- Regular Treasurers Reports were received and approved, aligned with the fiduciary responsibilities of the Board of Directors.

Student Actions:

- ISPOR Student Chapters at the following universities were made official: City University London (UK), PCOM – School of Pharmacy Georgia Campus (USA), Utrecht University (The Netherlands), Groningen University (The Netherlands), Kerala University of Health Sciences, Nirmala College of Pharmacy-Ernakulum District (India), Pontificia Universidad Javeriana/Javeriana University, Clinical Epidemiology & Biostatistics, Department (Colombia), Bombay College of Pharmacy-Mumbai (India), Jinan University, College of Pharmacy (China), and First Moscow State Medical University (Russia).

Regional Chapter Actions:

- Regional Chapters in the following geographies were made official: Kenya Chapter, Northeast China Chapter, Georgia Chapter, India-Telangana Chapter, Kyrgyzstan Chapter, Algeria Chapter, Lebanon Chapter, South China Chapter, Cyprus Chapter, and Uruguay Chapter.

Publication – Value in Health Actions:

- Reappointment for a 2nd term Co-Editors Andrew Lloyd, PhD, DPhil, Dan Greenberg, PhD, and Jalpa Doshi, PhD.

- Sarah Acaster, BSc, MSc, Kalipso Chalkidou, MD, PhD, and Danielle Whicher, PhD, MHS as new Co-Editors.
- Kati Copley-Merriman, BS, MSc, MBA as a new member of the Editorial Advisory Board Member.

Publication – *Value in Health Regional Issues* Actions:

- Imre Boncz, MD, MSc, PhD, Shu Chuen Li, BPharm, Cert Health Econ., Grad Dipl Bus, MAppSci, MBA, PhD, FACPPM (Hon) as Co-Editors.
- Reappointment of Nathorn Chaiyakunapruk, PharmD, Jenn Jianfei Guo, PhD, and Kenneth KC Lee, BSc, MPhil, PhD as Co-Editors for Asia.
- Reappointment for a 2nd term for Marcos Bosi Ferraz, MD, PhD, J. Jaime Caro, MDCM, FRCPC, PACP, and Victor Zarate, MD, MSc as Co-Editors for Latin America.
- Kasem S. Akhras, PharmD to the Editorial Advisory Board.
- Chee Jen Chang, PhD, Hengjin Dong, PhD, and Donald Yin, PhD to the Asia-Pacific Editorial Advisory Board.
- The ViHRI Excellence Article Award was approved to recognize the best articles in the publication each year.

Publications – *ISPOR CONNECTIONS* Actions:

- Support the repositioning and redesign of *ISPOR CONNECTIONS* to provide more value for Members. *Value & Outcomes Spotlight* was launched in 2015 with a revised focus and refreshed cover, masthead, and content approach. The first issue published was the January/February 2015 issue.

Award Actions:

- The Board approved the awardees of the ISPOR Scientific Award as given at: http://www.ispor.org/awards/index_.asp and <http://www.ispor.org/awards/value-in-health-paper-of-the-year.asp>.
- The Board approved the recipients of the ISPOR Board of Directors Service Award as given at: <http://www.ispor.org/awards/service/service.asp> and the ISPOR Distinguished Service Awards as given at: <http://www.ispor.org/awards/service/distinguish.asp>. ■

WEB CONNECTIONS

The National Directory of Managed Care Organizations

State Edition. A Managed Care Organization Directory/ Database just for your state! No need to buy a directory of managed care for the whole country – The National Directory of Managed Care Organizations State Edition is now available, providing key executive contacts and benchmarking business information on the managed care plans in your state. Available for purchase at: http://secure.campaigner.com/Campaigner/Public/show?7pjv4--3uwc8-awcgl65&_v=2.

Do you know of any websites that you would like to share with the ISPOR community? If so, contact *Value & Outcomes Spotlight* at: vos@ispor.org

ISPOR on LinkedIn

ISPOR LinkedIn Discussion Group

This discussion group, created by ISPOR, serves to promote discussions on topics such as outcomes research, comparative effectiveness, health technology assessment, and pharmacoeconomics (health economics), while providing an opportunity to network with like-minded individuals. The group is open to ISPOR members as well as interested individuals from academia, pharmaceutical, health care and insurance industries, governmental, and other related areas.

Please note: The views and opinions expressed therein do not necessarily reflect those of ISPOR.

Featured Discussions:

Novartis to Link Pricing of Heart Failure Drug to Clinical Drugs

Sign in to the ISPOR LinkedIn Discussion Group to post your comments on the topic of the pricing of heart medication based on clinical outcome instead of pay-for-pill model currently in use. **Contribute to the discussion at: <http://tinyurl.com/pl8nu8e>**

For UK Cancer Drug Fund, Does Cost Really Outweigh Clinical Efficacy in Their Decision-making Process?

Sign in to the ISPOR LinkedIn Discussion Group to post your comments on the discussion on cancer drug funding costs versus efficacy in the UK. **Contribute to the discussion at: <http://tinyurl.com/nd65zjd>**

Patient Voices Shaping Medicine on Patient Preferences

Sign in to the ISPOR LinkedIn Discussion Group to post your comments on this discussion on the importance of patient preferences in regulatory and research decision making. **Contribute to the discussion at: <http://tinyurl.com/ontxyg4>**